NCT02989623

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Academic / Other
• Sex: Male
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography (PET) works in detecting prostate cancer in patients with persistently elevated prostate specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound made of a radioactive agent attached to a molecule that looks like a hormone that binds to cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able to see tumors at an earlier stage than the standard of care.

Detailed description

PRIMARY OBJECTIVES: I. To assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect prostate cancer (PC), or absence thereof, within the prostate gland.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	Copper Cu 64 TP3805	Given Intravenously
PROCEDURE	Positron Emission Tomography and Computed Tomography Scan	Undergo copper Cu 64 TP3805 PET/CT scan

Timeline

• Start date: 2015-09-01
• Primary completion: 2019-04-24
• Completion: 2019-04-25
• First posted: 2016-12-12
• Last updated: 2025-04-24
• Results posted: 2025-03-27

Locations

1 site across 1 country: United States